Director/PDMR Shareholding

RNS Number : 6389I
Proteome Sciences PLC
22 March 2018
 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company announces that on 21 March 2018 Roger McDowell, a Non-Executive Director of the Company, sold 500,000 ordinary shares of 1 pence each ("Ordinary Shares") at a price of 3 pence per Ordinary Share and bought, into his SIPP, 500,000 Ordinary Shares at a price of 3.006 pence per Ordinary Share (the "Transfer").

Following the Transfer, Mr McDowell's beneficial interest in the Company remains at 2,500,000 Ordinary Shares representing approximately 0.91% of the issued share capital of the Company.

For further information:

Proteome Sciences plc

Jeremy Haigh, Chief Executive Officer                       Tel: +44 (0)20 7043 2116

Ian Pike, Chief Scientific Officer


Stefan Fuhrman, Finance Director

 

finnCap Limited (Nominated Adviser/Broker)

 

        

Geoff Nash/James Thompson

        Tel: +44 (0)20 7220 0500

Tony Quirke (broking)


               

About Proteome Sciences plc. (www.proteomics.com):

Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

 Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Roger McDowell

2.               

Reason for the Notification

a)

Position/status

Non-Executive Director

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Proteome Sciences plc

b)

LEI

213800Q62ICXANKU2986

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1p each

Identification code

GB0003104196

b)

Nature of the transaction

Purchase and sale of shares

c)

Price(s) and volume(s)

500,000 Ordinary Shares bought at 3.006p per Ordinary Share

500,000 Ordinary Shares sold at 3.000p per Ordinary Share

 

d)

Aggregated information:

·      Aggregated volume

·      Price

500,000 Ordinary Shares bought at 3.006p per Ordinary Share

500,000 Ordinary Shares sold at 3.000p per Ordinary Share

 

e)

Date of the transaction

21 March 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHSEMFDEFASEFD
UK 100

Latest directors dealings